Matrix Metalloproteinase-9: A Key Biomarker for Prognosis in Acute Ischemic Stroke

This article systematically elucidates the pivotal role of matrix metalloproteinase-9 (MMP-9) in the pathological progression of acute ischemic stroke, analyzes its close association with blood-brain barrier disruption, hemorrhagic transformation, and neurological functional outcomes, and further introduces the application value of murine MMP-9 recombinant protein in basic research and preclinical testing.

Recent Advances
Product Information

Recent Advances

Matrix Metalloproteinase-9: A Key Biomarker for Prognosis in Acute Ischemic Stroke

Summary
This article systematically elaborates on the central role of matrix metalloproteinase-9 (MMP-9) in the pathological process of acute ischemic stroke, analyzes its close association with blood-brain barrier disruption, hemorrhagic transformation, and neurological functional prognosis, and introduces the application value of mouse MMP-9 recombinant protein in basic research and preclinical testing.

I. Molecular Characteristics of MMP-9 and Its Pathological Significance in Cerebrovascular Diseases.

Matrix metalloproteinase-9 (MMP-9), also known as gelatinase B or 92 kDa type IV collagenase, is one of the largest members of the matrix metalloproteinase family. This enzyme is produced by various cells, including monocytes, macrophages, neutrophils, and vascular endothelial cells, and is secreted as an inactive zymogen. After proteolytic cleavage, it is converted into a catalytically active mature enzyme. MMP-9 can degrade the main components of the basement membrane—type IV collagen—as well as key structural components of the blood-brain barrier, such as the tight junction protein ZO-1. Following cerebral ischemia, the expression level of MMP-9 is significantly upregulated, inducing vasogenic edema and hemorrhagic transformation. Its excessive activation is considered an important pathological link in mediating ischemic brain injury.

II. Clinical Evidence of Serum MMP-9 and Prognosis in Acute Ischemic Stroke Patients.

There is a clear quantitative relationship between serum MMP-9 levels and clinical prognosis in acute ischemic stroke patients. A large-sample study based on the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS) (including 3,186 patients) showed that after adjusting for confounding factors such as age, sex, and baseline stroke severity, each standard deviation increase in serum MMP-9 levels (0.32 ng/mL) was associated with a 16% increased risk of the composite endpoint of death and severe disability within 3 months (OR=1.16, 95% CI: 1.06–1.28). The study also found that adding serum MMP-9 to the conventional risk factor model significantly improved the predictive ability for death or severe disability outcomes (net reclassification index 9.1%, integrated discrimination improvement index 0.4%). Another longitudinal study involving 42 acute ischemic stroke patients further demonstrated that a sustained decrease in MMP-9 levels after treatment was significantly associated with good prognosis, and the dynamic change pattern had greater predictive value for prognosis than a single baseline measurement.

III. Validation of MMP-9's Injury Mechanism in Ischemic Stroke Experimental Models.

Animal experiments provide direct causal evidence for the pathogenic role of MMP-9. In the C57BL/6J mouse transient middle cerebral artery occlusion model, MMP-9 protein levels were significantly elevated on days 1 and 3 after cerebral ischemia, accompanied by enlarged cerebral infarction area, aggravated cerebral edema, and neurological deficits. MMP-9 gene knockout mice exhibited significantly smaller cerebral infarction volumes and markedly improved behavioral abnormalities compared to wild-type controls, confirming that MMP-9 deficiency can alleviate ischemic neuronal injury. Another experimental study further indicated that prolonged ischemia time (1 to 4 hours) and recombinant tissue plasminogen activator treatment both dose-dependently increased MMP-9 expression, and MMP-9 expression levels were significantly positively correlated with cerebral infarction volume, brain swelling, and hemorrhage volume. Meanwhile, some studies suggest that MMP-9 may participate in neurovascular remodeling during the late phase of ischemic brain injury, indicating its "double-edged sword" nature—harmful in the acute phase but potentially beneficial during recovery.

IV. Applications of Mouse MMP-9 Recombinant Protein in Research and Testing.

In MMP-9-related basic research and preclinical testing, high-quality mouse-derived MMP-9 recombinant protein is a core tool for various experimental systems. The amino acid sequence (20-730 aa) corresponds to the full-length mature form of mouse MMP-9, and the C-terminal His tag enables high-purity purification through immobilized metal affinity chromatography (IMAC), while also facilitating Western Blot detection or immunoprecipitation experiments using anti-His tag antibodies. This recombinant protein has been applied in multiple research scenarios: as a standard for quantitative detection in ELISA kits, for preparing biotinylated detection antibodies, and as an immunogen for generating specific antibodies for immunohistochemical analysis.

To meet the above research needs, UniLove provides MMP-9 His Tag Protein, Mouse, which is suitable for MMP-9 activity assays (such as fluorescent substrate Mca-PLGL-Dpa-AR-NH2 hydrolysis detection) and as a standard for quantitative analysis of MMP-9 levels in serum or tissue samples from animal models.

V. Conclusion.

As a key enzyme that degrades the basement membrane and tight junction proteins of the blood-brain barrier, MMP-9 plays a central role in driving injury during the pathological process of acute ischemic stroke. Clinical studies consistently confirm that serum MMP-9 levels are an independent predictor of death and severe disability within 3 months in stroke patients, and its dynamic change pattern has significant prognostic value. Mouse MMP-9 recombinant protein, as an essential tool for basic research and preclinical testing, provides a critical material foundation for in-depth analysis of the enzyme's mechanism of action and the development of targeted intervention strategies.

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next